“In order to realise our goal of ensuring all melanoma patients receive a personalised approach to their diagnosis and treatment, collaboration is vital. Through key partnerships, we know that we can maximise the availability of our diagnostic test to enable a more...
The team at AMLo Biosciences is excited to receive publication of their latest USA patent. The filing for “The Clinical Management of Oropharyngeal Squamous Cell Carcinoma” has just been published in the USA. The patent filing describes how the biomarker, AMBRA1,...
Avero Diagnostics launches test for early-stage melanoma progression with AMLo Biosciences Avero Diagnostics (Bellingham (Washington) and Irving (Texas), USA) today announced the U.S. launch of AMBLor®, for identification of early-stage melanomas at low risk of...
We are delighted to announce that our very own CSO, Professor Penny Lovat, has been shortlisted for Woman Entrepreneur of the Year at the Cancer Research Horizons Innovation and Entrepreneurship Awards 2022 #IEAwards22.These prestigious annual awards recognise the...
AMLo Biosciences Limited is a company registered in England and Wales. Company # 11004534
Trading address: Newcastle University, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom
Registered address: c/o RMT Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG, United Kingdom
VAT # 285288950
Sign up for our newsletter